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Section 1 
INTRODUCTION 
Development and evolution of a disease are dynamic processes that, from a molecular point of 
view,  involve  changes  in  some  gene  expression  levels  in  the  involved  organs  and  cells.  A 
possible approach to study the behavior of such dynamic phenomena is to sample individuals, 
tissues or other relevant units at subsequent time-points throughout the progression. In this thesis 
we  focused  on  two  pathological  conditions:  chronic  lymphocytic  leukemia  (CLL)  and 
Waldenström’s  macroglobulinemia  (WM).  In  the  first  case  we  sought  genes  responsible  for 
different prognosis of CLL and tried to classify patients with an undefined prognosis. In the 
latter case we sought genes responsible for the evolution of IgM monoclonal gammopathy of 
undetermined significance (IgM MGUS) in Waldenström’s macroglobulinemia. 
To gain our goals, we used a tool, Sample Progression Discovery (SPD), developed by Peng Qiu 
et al. (1). This software, given gene expression data, extracts those features that, by gradually 
changing  their  expression  values  throughout  samples,  are  responsible  for  leading  some 
biologically meaningful process. A progression is not necessarily temporal: can also represent 
the  disease  evolution,  or  any  other  kind  of  progression,  provided  an  ordering  criterion  was 
previously specified. 
CLL  has  been  widely  studied  and  two  prognosis  classes  have  been  defined,  based  on  two 
biomarkers: the mutational status of IgVH and the expression of ZAP70. An un-mutated status of 
IgVH together with positive expression of ZAP70 is correlated to a poor prognosis and the need 
of treatment. On the other hand, a mutated status of IgVH and negative expression of ZAP70 is 
related to a positive prognosis and no treatment is provided. Some uncertainty arises when, in a 
patient,  the two biomarker  values are such that  the classification into one of the prognostic 
classes is not possible,  i.e. the patient shows mutated IgVH and ZAP70 positive expression. 
Hence, we tried to establish how to consider such undefined cases. 
Regarding MGUS and WM, recent studies showed that MGUS is the most common plasma cell 
dyscrasia and is associated with a lifelong risk of progression to multiple myeloma or related 
disorders  (2).  Thus we used SPD to  have a better understanding on such evolution  and the 
involved genes. 2 
After a first part of the thesis, during which we had to evaluate how to set SPD parameters and 
how to preprocess data, we went into a second part. Indeed, high-throughput expression data are 
affected by noise as the number of genes is great (~5∙10
4), whereas the number of samples for 
each patient is one or two. In the latter part, we actually applied the method to reach our aims. 
 
 
1.1.  Extraction of temporal dynamics from gene expression data 
High-throughput expression data can be used to infer temporal orderings by assuming that the 
process  evolution  can  be  detected  by  relatively  smooth  and  continuous  changes  in  the 
transcriptome (3). 
The estimate of accurate time series for biological processes is a hard task, due to the complexity 
of the problem. First of all, it is not always linear. For example, in the formation of blood cells, 
hematopoietic stem cells can differentiate in both myeloid and lymphoid cells. The latter two are 
the starting point of several parallel pathways, eventually leading to all blood cell types (4). 
 
 
Figure 1 
 
Besides the process itself, a further issue concerns the experiment to extract genetic material 
from  cells  for  gene  expression  analysis.  Indeed,  time  series  data  are  usually  drawn  from  a 
population  of  cells  and,  if  they  are  not  synchronized,  samples  can  contain  mixtures  of  the 3 
temporal  process.  Moreover,  heterogeneity  among  the  members  of  the  population  further 
complicates  the  temporal  samples  and  can  lead  to  ambiguous  situations,  in  which  sample 
orderings  are  correct  with  respect  to  absolute  time,  but  don’t  follow  the  dynamics  of  the 
biological process. 
 
 
1.2.  Chronic Lymphocytic Leukemia 
Chronic Lymphocytic Leukemia (CLL) is a chronic inherited lymphoproliferative disorder. It is 
the most common type of leukemia in Western countries, and is characterized by an increasing 
amount  of  mature-looking  immuno-incompetent  lymphocytes;  95%  being  B  cells.  The 
amassment of the clonal cell population occurs in blood, bone marrow, lymph nodes and spleen. 
The diagnosis of CLL is conventionally set in the presence of more than 5,000 small mature-
appearing lymphocytes per μl of peripheral blood. It is more common in males than in females, 
and affects especially elderly people. The etiology of CLL is still being investigated, as it is not 
known yet, but seems reasonable that the genetic predisposition may be the best explanation. In 
fact there is a higher prevalence of the disease in the family of the patients and there is no 
established role of the environment as inducing or influencing factor (5). 
As a matter of fact, CLL is a disease with a highly variable course, mainly falling into two 
subclasses, the most important difference being the illness aggressiveness. For patients in whom 
the disease has a slow course, there is no need for a specific therapy, whereas, for those suffering 
from  a  more  aggressive  pathology,  treatment  is  urgently  needed.  CLL  patients  presenting 
leukemic cells that have rearranged genes coding for the variable region of the heavy chain of 
sIg (IgVH) with more than 2% mutations are in general considered good prognosis patients, 
whereas those ones who do not show IgVH mutations have in general worse prognosis (6). As the 
DNA  sequencing  to  determine  the  status  of  IgVH  mutation  is  expensive  and  not  usually 
performed  in  all  clinical  contexts,  several  studies  aimed  to  find  alternative  factors  and 
biomarkers that can be correlated to such a difference. 
Nowadays, one well established of such markers is ZAP70, an intracellular protein that triggers 
activation signals delivered to T lymphocytes and natural killer cells by surface receptors for 
antigens. It is rarely present in normal B cells, but has been found in B cells from patients with 
CLL (6). 
Indeed, DNA analysis on gene expression of B cells showed ZAP70 expression to be strongly 
associated with mutational status of the IgVH gene. More specifically, further analysis confirmed 
that ZAP70 positivity is related to an un-mutated IgVH gene status, whereas ZAP70 negativity is 4 
associated with a mutated IgVH gene status (7). Thus, according to the combination of these two 
conditions, patients can be stratified into two prognostic groups (8): 
  positive prognosis, characterized by mutated IgVH and ZAP70 negative (M-ZAP70
-); 
  poor prognosis, characterized by un-mutated IgVH and ZAP70 positive (UM-ZAP70
+). 
Other independent molecular markers in CLL include surface CD38 expression and the presence 
of specific chromosomal aberrations, such as trisomy 12 and 11q22-23, 13q14, 6q21, 17p13 
deletions (5). More recently, lipoprotein lipase (LPL) expression has been shown to correlate 
with  IgVH  mutational  status  (9),  as  well  as  deregulation  of  expression  of  genes  coding  for 
enzymes controlling lipid metabolism (8). 
 
Prognosis 
Biomarkers 
IgVH mutational status  ZAP70 expression 
POSITIVE  mutated  - 
POOR  un-mutated  + 
Table 1 
 
 
1.3.  IgM Monoclonal Gammopathy of Undetermined Significance 
and Waldenstrӧm’s Macroglobulinemia 
MGUS is an asymptomatic premalignant disorder characterized by limited monoclonal plasma 
cell proliferation in the bone marrow and absence of end-organ damage. MGUS is differentiated 
from multiple myeloma and related disorders based on the presence or absence of end-organ 
damage that can be attributed to the plasma cell disorder. It is characterized by a serum IgM 
concentration lower than 3.0 g/dL, infiltration of clonal plasma cells in the bone marrow lower 
than 10% and the absence of end-organ damage. Among all MGUS cases, approximately 15% 
involves serum IgM paraprotein. It is more common in men than women and in whites than 
blacks.  Patients  diagnosed  IgM  MGUS  have  an  increased  risk  of  Waldenstrӧm’s 
macroglobulinemia and, therefore, IgM MGUS is considered a precursor of WM (10). 
WM  is  a  clonal  IgM  monoclonal  protein-secreting  lymphoid  and  plasma  cell  disorder.  It  is 
defined as an IgM monoclonal gammopathy with infiltration of clonal plasma cells in the bone 
marrow greater than 10%. Smoldering Waldenstrӧm’s macroglobulinemia (also referred to as 
indolent or asymptomatic WM) is defined as serum IgM monoclonal protein level greater or 
equal to 3g/dL and/or bone marrow lymphoplasmacytic infiltration greater or equal to 10% and 5 
no evidence of  end-organ damage, such  as  anemia, constitutional  symptoms,  hyperviscosity, 
lymphadenopathy, or hepatosplenomegaly (2). 
Patients  with  IgM  MGUS  and  smoldering  WM  have  an  overall  survival  rate  similar  to  the 
general population and should not be considered to have a malignant disease. 
 
Diagnosis  IgM concentration [g/dL]  Bone marrow infiltration [%]  End-organ damage 
IgM MGUS  <3  <10  no 
WM  <3  <10  yes 
sWM  ≥3  ≥10  no 
Table 2 
   6 
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Section 2 
DATA 
As previously explained, this thesis is divided into two parts. 
The main objective of the first part was to understand how to handle SPD. More specifically, we 
faced two main issues: selection of differentially expressed genes and the parameter setting. 
These two problems are closely connected, as they both affect the number of genes that are 
actually used by SPD to extract a progression. 
To come up with an appropriate strategy of gene selection and suitable parameter values, we 
proceeded in the following way. Starting from microarray expression data belonging to patients 
suffering from CLL with known prognosis, we made five different selections of genes, as further 
explained later on, and tested SPD by checking if it could classify correctly patients in the two 
prognostic groups. For each of the five selections provided to SPD, we set the standard deviation 
threshold within a range of values and evaluated the classification error for each of them. 
 
During the second part of the thesis, we used two other data sets to obtain different kind of 
information for two different diseases: CLL and WM. 
Concerning CLL, we used the same data set used for the first part with a couple of differences: 
two microarrays have been added; a third class of patients with uncertain prognosis has been 
taken  into  account,  as  the  objectives  of  this  part  were  to  evaluate  how  to  treat  undefined 
prognosis  patients  and  try  to  classify  one  patient  for  which  IgVH  mutational  status  was  not 
available. 
Regarding WM, we used a totally different data set. We analyzed microarray data belonging to 
97 patients.  Twenty-five of them were  diagnosed  IgM  MGUS, the remaining 72 with  WM. 
Samples were taken from different cell types: CD19 antigen positive, CD138 antigen positive 
and antigen negative. 
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2.1.  CLL Data set 
We  examined  microarray  expression  data  belonging  to  patients  affected  by  Chronic 
Lymphocytic Leukemia, diagnosed at the Division of Hematology at Niguarda Hospital, Milan, 
Italy. They were submitted to a software application called Sample Progression Discovery (1) to 
extract a progression underlying gene expression data. Microarray data belong to 112 patients 
divided into three classes: class 1 with mutated IgVH and ZAP70
-, class 2 with un-mutated IgVH 
and  ZAP70
+,  class  3  including  both  un-mutated  IgVH  and  ZAP70
-  and  mutated  IgVH  and 
ZAP70
+. Peripheral blood mononuclear cells (PBMCs) from all samples were isolated by Ficoll 
density gradient centrifugation (Invitrogen, Milan, Italy) at 800 rpm for 20 minutes and soon 
after CD19
+ cells were purified using MACS CD19 Microbeads (Miltenyi Biotech, Bologna, 
Italy) from fresh PBMCs of all 112 CLL patients following the manufacturer’s instructions; the 
purity  of  CD19
+  cell  was  greater  than  97%  as  determined  by  flow  citometry.  CD19
+  cells 
(       ) were resuspended in 100 µl of RNAlater (Ambion, Applied Biosystems, Milan, Italy) 
and stored in a CLL cell bank at -20°C until RNA extraction was performed (8). 
 
 
2.2.  WM/MGUS Data set 
This data set consisted of 97 probes belonging to patients diagnosed either with WM or with IgM 
MGUS. Bone marrow CD19
+, CD138
+ and NEG cells were isolated from WM patients and IgM 
MGUS patients as shown in Table 3. Bone marrow mononuclear cells from all samples were 
isolated by Ficoll density gradient centrifugation at 800 rpm for 20 minutes. Right after CD19
+ 
cells  were  selected  using  MACS  CD19  Microbeads  (Miltenyi  Biotech,  Bologna,  Italy); 
afterwards CD138
+ cells were positively isolated from the collected CD19
- cells using MACS 
CD138  Microbeads  following  the  manufacturer’s  instructions  (Miltenyi).  Gene  expression 
profiling has been performed on total RNA extracted from bone marrow CD19
+, bone marrow 
CD138
+ and NEG cells. The concentration and quality of the RNA samples have been evaluated 
using Nanodrop 2000 UV-vis spectrophotometer (Euroclone, Milan, Italy). 
 
97 probes 
38 CD19
+ 
27 WM 
72 WM 
25 IgM MGUS 
11 IgM MGUS 
31 CD138
+ 
24 WM 
7 IgM MGUS 
28 NEG 
21 WM 
7 IgM MGUS 
Table 3 9 
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Section 3 
SAMPLE PROGRESSION DISCOVERY 
Peng Qiu et al. developed a tool, called Sample Progression Discovery (SPD), which aims to 
reveal biological progression underlying a microarray data set. 
 
Based on the hypothesis that to any step of biological progression corresponds a gradual change 
in  expression  levels  of  some  subsets  of  genes,  SPD  assumes  that  individual  samples  of  a 
microarray data set are linked by an unknown biological process, and that each sample represents 
one  unknown  point  along  the  progression  of  such  process.  So  SPD  can  be  useful  when 
microarray samples are available but their ordering is unknown and not necessarily linear. In the 
latter case, SPD can detect branching points along the progression. It also has a feature selection 
ability that enables to reveal the candidate genes that regulate that progression. 
 
SPD was tested on a variety of biological processes such as differentiation, development, cell 
cycle and disease progression. Microarray data sets, obtained by sampling a biological process at 
different  points  along  its  progression,  were  provided  to  SPD,  without  any  other  piece  of 
information regarding either the progression itself or meaningful gene features. 
 
 
3.1.  Methods 
SPD is implemented in Matlab 7 (The MathWorks, Natick, MA) using a graphical user interface. 
The  software,  at  its  second  version,  is  available  and  freely  downloadable  on  the  internet  at 
http://odin.mdacc.tmc.edu/~pqiu/software/SPD/. 
 
The algorithm executes four main steps on gene expression data to finally extract a  disease 
progression from expression data. 11 
At first, co-expressed genes are grouped together into modules via clustering. This is necessary 
to speed up the analysis. The method used to cluster and obtain consistent gene modules is a 
consensus  k-means  agglomerative  algorithm.  The  stopping  criterion  is  the  desired  module 
coherence that is computed as the average Pearson correlation between each gene in the cluster 
and the cluster mean, and it is chosen by the user. 
Information  about  the  behavior  of  genes  in  the  same  module  is  translated  into  a  minimum 
spanning tree (MST): each MST represents a group of highly co-expressed genes following the 
same pattern. Each node is a microarray sample and the edges are weighted by the distance 
between sample gene expression profiles. By definition, given a connected, undirected graph, a 
spanning tree is a sub graph that is a tree and connects all the vertices together. If a weight is 
assigned to each edge, the minimum spanning tree is the ST with weight less than or equal to the 
weight of every other ST. Hence, a MST connects samples that are closer to each other. Using 
such  a  structure  to  describe  a  progression  enables  SPD  to  find  progressions  with  branching 
points, as well as linear ones. 
Modules  that  share  common  MST  structure  are  selected;  the  overall  MST,  representing  the 
global progression, is pieced together using only the genes belonging to selected modules. 
 
Figure 2 
 
To assess the resemblance of progression patterns, SPD compares modules and MSTs. More 
specifically, it computes the earth mover’s distance between all the modules and all the genes. 
This is one of the major differences between the latter version of SPD and the former one. To 
clustering genes 
create clusters of co-expressed genes 
construction of minimum spannining tree 
create a MST for each cluster 
module selection 
compare and select clusters with similar MST 
structure 
final progression 
create a MST based on genes in the selected 
clusters only 12 
identify  similar  modules  in  terms  of  progression,  SPD  generates  a  similarity  matrix.  It  is 
necessary to choose a threshold that determines whether the fit between a module and a tree is 
significant. This parameter is user defined and its default value is 0.05: it means that, among all 
the module-tree pairs, the top 5% with most significant earth mover’s distances are considered to 
“fit well with each other”, and are used to construct the PSM. 
The selection of modules needed to obtain the overall MST, thus the sought progression, is done 
manually. The user decision is supported by the progression similarity matrix. Each element 
represents the number of trees that are concordant with the two correspondent modules. Genes 
belonging to the selected modules are the ones supporting the overall progression. Hence, the 
feature selection is made by evaluating the statistical concordance between each gene module 
and each MST. 
 
 
3.2.  SPD step by step 
3.2.1.  Input format 
To start using SPD is necessary to prepare a file .mat which contains at least three variables: 
  probe_names: N∙1 cell array with the N names of genes or features; 
  exp_names: 1∙M cell array with the M names of samples or arrays; 
  data: N∙M matrix of expression data. 
Two optional variables can be added for the color coding of results: 
  color_code_names: K∙1 cell array with a name for each desired color code; 
  color_code_vectors: K∙M matrix with the clinical info corresponding to each color code. 
 
Once the input file is ready, it can be loaded. It is also possible to load previous results. 
 
3.2.2.  Gene filtering 
SPD  gives  the  users  three  options  to  filter  genes:  standard  deviation  threshold,  number  of 
acceptable  nulls  per  gene  and  throw  away  “_x_at”  probes.  If  more  appropriate  filtering  is 
needed, users can customize their own selection when preparing the input file, and then ignore 
the filtering options in the GUI. 
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The aim of the first option is to keep only those genes that are differentially expressed along the 
probes for the following analysis. In fact SPD computes for each gene the standard deviation σ 
on the expression values and all the genes with σ<σth are not taken into account. 
 
The second and the third options allow the user to “clean” the data set by removing all the genes 
with  more  NULL  entries  than  acceptable  and  the  “_x_at”  probes.  In  the  Affimetrix  U133a 
GeneChip the “_at” suffix designates a unique probe set, while “_s_at” and “_x_at” suffixes 
designate probe sets that can cross hybridize with multiple genes (11). 
 
The software shows the basic information after filtering. 
 
3.2.3.  Clustering 
The aim of clustering is to group together highly co-expressed genes into modules so that the 
number of gene expression patterns to be tested is reduced. The algorithm chosen to cluster is an 
iterative consensus k-means procedure. 
 
A k-means clustering algorithm performs the following steps: 
1.  randomly select k initial centers; 
2.  assign each element to the closest center according to a chosen metric; 
3.  re-calculate centers; 
4.  repeat 2 and 3 until a stopping condition is reached. 
The number of clusters k has to be previously decided. SPD uses k=2 and iterates the algorithm 
for L=200 times. 
Starting from the N∙M expression data matrix, it creates a N∙L matrix in which the (i, j) element 
represents the cluster assignment of gene i at iteration j. To have the consensus, k-means is 
applied again on the N∙L matrix. 
At this point, SPD creates modules by further clusterization based on the coherence of already 
existing clusters. The coherence is computed as the average Pearson correlation between each 
gene in the cluster and the cluster mean. If the coherence is less than a pre-specified threshold, 
such cluster is partitioned by iterating the procedure until all the clusters have coherence greater 
than the threshold that is set equal to 0.9. 
The modules obtained so far, are not the ultimate ones. To be sure they are not similar to each 
other, they are compared pairwise. If the Pearson correlation of two modules centers is higher 14 
than a user defined threshold, the modules are merged together. The suggested value for module 
coherence is 0.7 but, if the histogram of all the pair-wise correlations shows a heavy tail, a higher 
coherence parameter may be more appropriate. 
 
3.2.4.  Construct MSTs – Compare modules and MSTs 
SPD  builds  a  minimum  spanning  tree  for  each  module,  based  on  expression  data  of  genes 
belonging to the same module. 
 
Given a connected, undirected graph          , with V the set of vertices and E the set of 
edges, for each edge           a cost function         is defined. A minimum spanning tree 
is an acyclic subset       that connects all of the vertices and it is such that the total weight 
                         is minimum. 
 
All the minimum spanning trees built on gene modules have samples as vertices and the weight 
of  an  edge  connecting  samples         is  defined  as  the  Euclidean  distance  between  gene 
expression profiles of sample u and v. This way, MSTs connect samples that are similar to each 
other, but they are slightly different for a gradual change in gene expression. 
 
The comparison between modules and trees is made by using the earth mover’s distance (EMD) 
as a metric to build a progression similarity matrix. The goal is to seek for statistical concordance 
between all the modules and all the trees and, hence, determine the progression supported by 
meaningful features. 
The earth mover’s distance is the extension of the notion of distance between single objects to 
distance between distributions.  Given two distributions,  one can be seen as  a mass of earth 
spread in the space, the other one as a collection of holes in the same space. If needed one can 
switch what is called earth and what is called holes so that there is always at least as much earth 
as needed to fill all the holes completely. The EMD measures the least amount of work necessary 
to fill the holes with earth, where work corresponds to transporting a unit of earth by a unit of 
ground distance (12). 15 
The computation of EMD is based on the transportation problem. It deals with suppliers and 
consumers: suppliers have sources available to satisfy the consumer’s demand. The goal is to 
minimize the cost for shipping the sources. This is a bipartite network flow problem, since the 
nodes can be divided into two parts with all arcs going from one part to the other (13), as shown 
in Figure 3, which represents an example with three supplier and two consumers. 
 
The problem can be formalized as the following linear programming problem: let I be a set of 
suppliers, J a set of consumers, and cij the cost to ship a unit of supply from       to      . The 
solution is a set of flows fij that minimize the overall cost  
            
       
 
subject to the following constraints: 
         
for      ,      ; 
 
     
   
     
for      , where yj is the total capacity of consumer j; 
 
     
   
     
for      , where xi is the total supply of supplier i. 
 
The first constraint allows shipping of supplies from a supplier to a consumer and not vice versa. 
The second constraint forces the consumers to fill up all of their capacities and the last constraint 
supplier 
consumer 
J 
cij 
I 
Figure 3 16 
limits the supply that a supplier can send to its total amount. A feasibility condition is that the 
total demand does not exceed the total supply: 
   
   
     
   
 
 
Once the transportation problem is solved, the earth mover’s distance is defined as: 
          
                      
                
 
                      
        
 
 
In general, the ground distance cij can be any distance and it will be chosen according to the 
problem to handle (12). 
 
3.2.5.  Identify modules similar in terms of progression 
The main step of SPD that enables the extraction of the final progression is the comparison 
between the expression of gene modules and trees constructed from other modules. Based on the 
statistical  concordance  between  al  the  modules  and  all  the  trees,  which  is  user  defined,  a 
progression  similarity  matrix  is  derived.  From  this  matrix,  similar  modules  are  easily 
recognizable,  because  they  lie  on  the  diagonal  and  they  have  red  shade,  darker  or  lighter 
depending on greater or smaller similarity. Since the number of modules  in  the progression 
similarity matrix is usually small, the module selection is to be performed manually. 
 
Given the expression data of a gene module in M samples, a M∙M distance matrix D is defined, 
where Dij is the EMD distance between the gene expression profiles i and j. A second M∙M 
matrix A is defined to represent the tree structure. It is an adjacency matrix in which Aij=1 if 
samples i and j are directly connected in the tree, otherwise Aij=0. 
The concordance between a gene module and a tree is then defined as the concordance between 
the distance matrix D and the adjacency matrix A: 
         
     
 
In this way, the distance on the progression between connected samples is small whereas the 
distance between not connected samples is relatively greater. To derive the p-value of s, SPD 
performs  1000  random  permutations.  The  threshold  to  compare  the  p-value  is  user  defined, 
thought the suggested values to use are 0.05 (the default), 0.10 and 0.15. 17 
 
Once the user chooses similar modules by visual inspection of the progression similarity matrix, 
SPD creates the overall progression based on genes belonging to those modules. 
 
 
3.3.  Results and discussion 
SPD underwent trials to prove its potentiality of retrieving biological processes given microarray 
samples. The authors prepared several microarray data sets to test SPD. For each data set, the 
actual underlying progression was known, but was not provided to SPD, and was used merely as 
a comparison to validate the results. 
The data sets included a cell cycle time series, B-cell differentiation data and a prostate cancer 
microarray data set. In all of the trials, SPD was able to recover respectively the correct time 
order of the samples, the correct order of different stages of normal B-cell differentiation, and the 
progression consistent with disease evolution. Moreover, the genes identified and involved to 
assess the progression were consistent with the biological process itself. 
 
SPD has some distinctive features which make its analysis on microarray data more complete 
than other previously adopted techniques. Unlike other machine learning algorithms, such as 
unsupervised clustering, supervised classification and statistical tests for differential expression, 
whose  goal  is  to  identify  discrepancies  between  different  sample  groups  by  assuming  that 
samples in the same group are similar, SPD is based on an alternative approach. As it considers 
individual  samples  as  different  points  along  an  unknown  biological  progression,  it  has  the 
potential to discover how samples progress both within and across groups. 
Furthermore, it is capable to extract the genes associated with the progression with no a priori 
knowledge about meaningful gene features. 
One  of  the  key  aspects  of  this  tool  is  the  way  used  to  measure  the  similarity  among  gene 
modules. Unlike methods using correlation and regression, in which the expression profiles of 
gene modules are directly compared with each other, in SPD the comparison is assessed via 
minimum spanning trees. MSTs represent progression patterns and the similarity between gene 
modules is based on the number of MSTs they share. 
This way, SPD can identify similarities that correlation and regression-based analysis may miss. 
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Section 4 
PARAMETER SETTING 
To study the evolution of chronic lymphocytic leukemia, we decided to use SPD as a tool to 
assess the progression of the disease. First of all, we needed a method to decide how to set 
parameters in SPD. As here in below explained, results may greatly vary depending on such 
parameters; hence we tested SPD on 5 groups of genes. Each group was obtained via different 
methods of selection, by coding with R language (14). 
 
 
4.1.  Input configuration 
We provided SPD with different sets of data. All were from the same microarray data set of a 
cohort of 112 patients, each group differing from the others for the gene selection. Out of the 112 
patients, only those with a known prognosis were considered, namely 89. 
The  data  set  had  to  be  normalized  because  samples  were  taken  at  different  times,  so  we 
multiplied each column by a scale factor (columns represent patients, rows represent probes). We 
computed the median for each column and then computed the overall median (median of the 
medians). Each scale factor was given by the overall median divided by the median of each 
column. Once data were homogeneous, we ordered patients according to their class and deleted 
those belonging to class 3. We obtained a matrix with N=54675 probes on the rows and 89 
patients on the columns, of which the first 61 belong to class 1, the remaining 28 to class 2. 
The first subset used corresponds to the overall data set with 54675 probes. 
The  second  subset  counted  677  differentially  expressed  genes  selected  using  Significance 
Analysis for Microarrays (15) and false discovery rate 5%. 
The third subset was obtained performing a SAM selection (15) on the data. It consisted of 2870 
genes. In order to accomplish such a selection, we used the sam function of Bioconductor (16) 
performed with 100 iterations and α=2.5%. No correction for multiple testing was used, so to 
gain a comparable number of probes to that of the group afterwards obtained. 20 
Probes  of  the  fourth  subset  were  extracted  using  MAD  and  Wilcoxon  test.  MAD  (Median 
Absolute Deviation) was computed on both classes. Five samples from each class were then 
randomly  chosen  for  100  times,  to  have  an  estimate  of  both  class  MAD  values.  Assuming 
samples of the two groups to be independent and to belong to two different populations with the 
same but unknown distribution, and the same standard deviation, Wilcoxon test was performed. 
Using a significance level given by Bonferroni correction α=0.025/N, 2320 genes were selected.  
The last subset is given by the union of the probes of the third and fourth data set, and contained 
4698 probes. 
That said, each group is referred to as in Table 4. 
 
Subset  Selection mode  # of genes 
1  CLL_89_tot  no selection  54675 
2  CLL_89_sam_fdr  sam fdr=5%  677 
3  CLL_89_sam  sam α=2.5%  2870 
4  CLL_89_mad  mad + wilcoxon  2320 
5  CLL_89_union  sam U mad  4698 
Table 4 
 
 
4.2.  Result evaluation 
As reported by Peng Qiu et al., and as had become clear during the thesis, SPD is very sensible 
to the input data, meaning that, depending on the genes provided, results may greatly vary. 
Particularly, we needed a criterion to evaluate how to set the user defined parameters in SPD. 
We focused mainly on the standard deviation threshold for gene filtering, because of the strong 
dependence of results on such parameter. To find a rational decision rule, we tested SPD on each 
group using different threshold values, and then attempted to extract those giving best results. 
Standard  deviation  threshold  values  used  ranged  between  0  and  the  maximum  value  still 
producing at least two meaningful modules, with a pitch of 0.1. SPD actually gave an error when 
building the progression similarity matrix if the modules to compare were less than two. For 
subset CLL_89_tot, the initial standard deviation value was not 0 but 0.5, due to very long 
running times to complete the computation of the clustering step and the comparison between 
modules. 
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In Figure 4 it is shown, as an example, the output of SPD. It is the results obtained from subset 
CLL_89_sam for standard deviation threshold value equal to 0.9. Blue dots represent patients 
with positive prognosis, whereas green diamonds represent patients with poor prognosis. 
 
 
Figure 4 
 
To evaluate the reliability of the results obtained, we checked whether the subdivision in the two 
prognostic classes was correctly or not recovered. The measure of correctness was made by 
manually counting how many samples were misclassified. And by dividing it by 89. 
 
Once we had the relative error trend and its average, we restricted the range of standard deviation 
values to those ones giving an “acceptable” error. As a general rule, we considered an error to be 
“acceptable” if it was below the average. 
 
Based on the chosen range of standard deviation threshold, we computed the pairwise distances 
between all the progressions obtained using the corresponding adjacency matrices. Given two 
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adjacency matrices A and B, defined as in section  3.2.5, and            , the distance was 
computed as the following score: 
   
         
           
 
Element Sij of matrix S is equal to 1 if and only if in one of the progressions there is an edge 
connecting two samples that is missing in the other one. Thus, the greater s is, the greater is the 
distance between the two progressions. The distance s was plotted versus                   
using boxplots. 
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For each subset and for each value of standard deviation threshold we obtained a progression of 
the same kind as the one shown in Figure 4. For each output given by SPD, we computed and 
plotted  the  relative  error  of  classification  and  the  number  of  filtered  genes  versus  standard 
deviation threshold values (Figure 5 and Figure 6). We got two plots for each subset of genes. 
Based on these figures, for each subset, we chose a range of standard deviation threshold. As a 
criterion to make such choice, we looked at the relative error trend, and we selected a range of 
values for which the error was below the average for that subset. Furthermore, we highlighted 
the number of genes filtered for the selected range of standard deviation threshold (Figure 6), 
and  we  computed  and  plotted  the  distances  between  progressions  versus  the  difference  of 
standard deviation threshold (Figure 7). 
 
Figure  5  shows  the  behavior  of  the  relative  classification  error  versus  standard  deviation 
threshold, for each subset of genes. 
 
It is evident from the average error trends that gene selection is essential. Indeed, when using all 
the  genes  of  the  microarray  to  find  a  progression,  SPD  produced  results  with  high 
misclassification  error,  regardless  of  the  standard  deviation  threshold  (Figure  5-A).  This 
experimental evidence suggests that gene expression values for the whole microarray include too 
much noise. Such noise exceeds the information content peculiar for that pathology. We can also 
see in Figure 6 that the number of filtered genes that produce good results varies a lot. 
In  Figure  5-B  the  average  classification  error  is  the  lowest  obtained,  meaning  that  in  the 
progressions most of the patients were recognized as belonging to their actual prognostic class. 
For this reason we decided not to select any restricted range of standard deviation threshold 
values. 
From the trend of classification error for CLL_89_sam subset (Figure 5-C) is clear which is the 
best range of standard deviation threshold values, and the average error is the second smallest 
obtained. The correspondent number of filtered genes is the highest, ranging from 1523 to 103. 
The third method of gene selection that we computed, producing subset CLL_89_mad is shown 
in  Figure  5-D,  was  the  second  worst  result  obtained.  Indeed,  the  average  relative  error  is 
approximately 14%. This result had also a negative influence on subset CLL_89_union, since it 
was given by the union of subset CLL_89_sam with subset CLL_89_mad. It seems fair to expect 
a result that is a combination of the two previous ones and, as a matter of facts, it is. In Figure 5-
E we can see that the error trend has common characteristics with trends in Figure 5-C and D. 26 
Moreover, the average error is about the average of the previous two averages, and so it is the 
number of genes for the selected range of standard deviation threshold. 
Concerning  the  distances  between  progressions,  from  Figure  7  we  can  see  how  different 
progressions are from each others. Even for a small variation in standard deviation threshold, 
resulting progressions presented heterogeneous structures. 
 
 
4.3.  Conclusions 
As expected, using rough data does not produce reliable results, as only a small fraction of genes 
is not specifically related to the disease. The greatest part of genes prevents SPD from recovering 
a progression, increasing the noise that exceeds the informative content. Thus, a selection of 
genes is absolutely necessary. 
Among the methods we used to reduce the number of genes to extract the most meaningful ones, 
SAM  selection  with  fdr=5%  (CLL_89_sam_fdr)  and  SAM  selection  with  α=2.5% 
(CLL_89_sam) gave the best results. SPD was able to classify subjects in the two prognostic 
classes, with low misclassification error. 
In particular, for subset CLL_89_sam, the average error was 8.3% and, for standard deviation 
threshold values ranging from 0.5 to 1.6, the error was below the average. The corresponding 
number  of  genes  used  to  produce  the  progressions  ranged  from  1523  to  103.  Subset 
CLL_89_sam_fdr, on the other hand, gave good results for standard deviation threshold values 
ranging from 0 to 2.1 and a number of genes ranging from 677 to only 23. The average error of 
classification was 4.6%, being the lowest obtained. 
 
The worst results after gene selection was given by subset CLL_89_mad. 
Knowing that results are strongly affected by the initial gene selection, as a general rule, we 
could  suggest  to  use  a  standard  deviation  threshold  value,  chosen  among  those  ones  giving 
acceptable results, that is as conservative as possible in regard to the number of genes. As a 
consequence, it seems reasonable to make several trials, and choose suitable parameter values by 
visual inspection of the results. 
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Section 5 
APPLICATION TO CHRONIC 
LYMPHOCYTIC LEUKEMIA 
After  evaluating  the  behavior  of  SPD  on  different  inputs  and  several  settings  of  standard 
deviation  threshold  parameter,  we  applied  it  to  another  two  data  sets  associated  to  chronic 
lymphocytic leukemia and Waldenström’s macroglobulinemia. 
 
 
5.1.  Gene selection 
Given the results previously obtained, for this part of the thesis, gene selection was performed by 
using significance analysis of microarrays (15) with false discovering rate 5%. Thus, from an 
initial amount of 54675 genes, only 4374 were selected. The number of probes, i.e. of patients, 
was 114 split in the following groups: 
1.  62 patients with positive prognosis (M-IgVH and ZAP70
-) referred to as “Positive”; 
2.  28 patients with poor prognosis (UM-IgVH and ZAP70
+) referred to as “Negative”; 
3.  23 patients with undefined prognosis (UM-IgVH and ZAP70
-, or M-IgVH and ZAP70
+) 
referred to as “NC”; 
4.  1 patient with unknown prognosis referred to as “NA”. 
This subset is referred to as CLL_114. 
 
CLL_114 
Class name  # of patients  Prognosis 
Positive  62  Positive 
Negative  28  Poor 
NC  23  Undefined 
NA  1  Non available 
Table 5 29 
5.2.  SPD results 
Basing on previous results and being aware that SPD is extremely sensible to the input, when we 
applied it to subset CLL_114, we used values of standard deviation threshold ranging from 0.5 to 
1.6. For each of them, we evaluated the error of classification as follows. As in this situation 
there were three classes to be distinguished, we exploited the fact that class “Negative” was 
clearly isolated from class “Positive” and class “NC”, for every value of standard deviation 
threshold. Thus, we assumed patients belonging to class “Positive” and class “NC” as being part 
of the same group, so that the error of classification could be computed as described in 4.2 for 
CLL_89  subsets.  As  shown  in  Figure  8,  relative  classification  error  is  much  more  regular 
compared to previous results, and close to the average value, which is 5.75%. 
 
 
Figure 8 
 
We show in Figure 9 one of the progression produced by SPD, to summarize the results obtained 
for this data set. 
SPD cuts off poor prognosis samples and groups together patients with a good or undefined 
prognosis. According to this result, patients presenting prognostic marker values not following 
the standard for prognostic classification, should be considered and treated as those ones with a 
positive prognosis. 
It is interesting to point out that patient “LLC043” precedes “LLC043.2”, which is actually the 
same patient who underwent RNA exam twice at different times. This patient has been stable 
since diagnosis, and is not being treated as presents a positive prognosis. Only one time, for 
sd=1.0, they were both misclassified, but still linked to each other. 
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A closer look to patients in class “NC” revealed that their association to patients with positive 
prognosis was due to the mutational status of IgVH. Indeed, IgVH is a more relevant prognostic 
biomarker, rather than ZAP70 expression. 
Another result to highlight is about patient “LLC160”. SPD classified it with classes “Positive” 
and “NC” patients for all standard deviation threshold values but for sd=1.4. Furthermore, to 
such value corresponds a relative classification error greater than the average. Hence, it could be 
considered to have a positive prognosis. When that was the case, “LLC160” position along the 
progression was either close to class “Negative” misclassified patients, or among class “Positive” 
and “NC” patients. 
 
 
Figure 9 
 
We chose, as the most representative progression, the one given by sd=1.2, because for this value 
the relative misclassification error is below average and subjects “LLC043”, “LLC043.2” and 
“LLC160” position reflects the overall outcomes previously depicted. 
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We extracted the gene lists actually used to build each progression and put them together in two 
different ways: we evaluated their union and intersection. For this data set and for the standard 
deviation threshold values considered, the union included 213 genes, as represented in Table 6, 
whereas the intersection was empty. Among all of those genes, the ones highlighted in the table 
have already been pointed out in several studies as being related to IgVH mutational status, and 
could be considered eligible candidate as additional prognostic biomarkers (8). 
For the sake of completeness, we performed a functional annotation clustering on genes reported 
in  Table  6.  We  used  the  “functional  annotation  clustering”  tool  available  on  DAVID 
Bioinformatics Resources (17), (18) to cluster together genes with similar annotation. Results are 
shown in Table 11 in Section 9. 
 
Table 6 
PROBE ID  GENE ID  GENE NAME 
205978_at  KL  klotho 
210401_at  P2RX1  purinergic receptor P2X, ligand-gated ion channel, 1 
1554733_at  MGC24125  hypothetical protein MGC24125 
227530_at  AKAP12  A kinase (PRKA) anchor protein 12 
222453_at  cybrd1  cytochrome b reductase 1 
227265_at  FGL2  fibrinogen-like 2 
204254_s_at  VDR  vitamin D (1,25- dihydroxyvitamin D3) receptor 
230287_at  SGSM1  small G protein signaling modulator 1 
214453_s_at  IFI44  interferon-induced protein 44 
206181_at  SLAMF1  signaling lymphocytic activation molecule family member 1 
1556209_at  CLEC2B  C-type lectin domain family 2, member B 
231356_at  LOC100131014  hypothetical LOC100131014 
215145_s_at  CNTNAP2  contactin associated protein-like 2 
230578_at  ZNF471  zinc finger protein 471 
209815_at  ptch1  patched homolog 1 (Drosophila) 
232584_at  TSHZ2  teashirt zinc finger homeobox 2 
1553196_a_at  FCRL3  Fc receptor-like 3 
212446_s_at  LASS6  LAG1 homolog, ceramide synthase 6 
238071_at  LCN10  lipocalin 10 
204083_s_at  tpm2  tropomyosin 2 (beta) 
212698_s_at  SEPT10  septin 10 
230831_at  Frmd5  FERM domain containing 5 
219255_x_at  Il17rb  interleukin 17 receptor B 
229552_at  LOC283454  hypothetical protein LOC283454 
202393_s_at  KLF10  Kruppel-like factor 10 
212985_at  Apbb2  amyloid beta (A4) precursor protein-binding, family B, member 2 
203030_s_at  Ptprn2  protein tyrosine phosphatase, receptor type, N polypeptide 2 
211637_x_at  LOC100126583  hypothetical LOC100126583 32 
224156_x_at  Il17rb  interleukin 17 receptor B 
226425_at  CLIP4  CAP-GLY domain containing linker protein family, member 4 
229344_x_at  RIMKLB  ribosomal modification protein rimK-like family member B 
218418_s_at  KANK2  KN motif and ankyrin repeat domains 2 
231303_at  NCRNA00158  non-protein coding RNA 158 
206978_at  CCR2  chemokine (C-C motif) receptor 2 
206100_at  CPM  carboxypeptidase M 
204646_at  DPYD  dihydropyrimidine dehydrogenase 
221802_s_at  KIAA1598  KIAA1598 
244740_at  MGC9913  hypothetical protein MGC9913 
223380_s_at  Lats2  LATS, large tumor suppressor, homolog 2 (Drosophila) 
238983_at  nsun7  NOL1/NOP2/Sun domain family, member 7 
219304_s_at  PDGFD  platelet derived growth factor D 
225897_at  MARCKS  myristoylated alanine-rich protein kinase C substrate 
215489_x_at  HOMER3  homer homolog 3 (Drosophila) 
213566_at  RNASE6  ribonuclease, RNase A family, k6 
204834_at  FGL2  fibrinogen-like 2 
211474_s_at  serpinb6  serpin peptidase inhibitor, clade B (ovalbumin), member 6 
203796_s_at  BCL7A  B-cell CLL/lymphoma 7A 
211643_x_at  IGKV3D-15  immunoglobulin kappa variable 3D-15 (gene/pseudogene) 
219300_s_at  CNTNAP2  contactin associated protein-like 2 
236918_s_at  LRRC34  leucine rich repeat containing 34 
204454_at  Ldoc1  leucine zipper, down-regulated in cancer 1 
207120_at  ZNF667  zinc finger protein 667 
234284_at  GNG8  guanine nucleotide binding protein (G protein), gamma 8 
219738_s_at  PCDH9  protocadherin 9 
226926_at  Dmkn  dermokine 
203642_s_at  Cobll1  COBL-like 1 
1560562_a_at  ZNF677  zinc finger protein 677 
223620_at  GPR34  G protein-coupled receptor 34 
225133_at  KLF3  Kruppel-like factor 3 (basic) 
209674_at  CRY1  cryptochrome 1 (photolyase-like) 
205414_s_at  RICH2  Rho-type GTPase-activating protein RICH2 
228557_at  L3mbtl4  l(3)mbt-like 4 (Drosophila) 
214720_x_at  SEPT10  septin 10 
212442_s_at  LASS6  LAG1 homolog, ceramide synthase 6 
216491_x_at  IGHV3-11 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 
216491_x_at  IGHV3-7 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 
216491_x_at  IGHG3 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 33 
216491_x_at  Ighg1 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 
216491_x_at  IGH@ 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 
216491_x_at  IGHM 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 
216491_x_at  ighv4-31 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 
214032_at  zap70  zeta-chain (TCR) associated protein kinase 70kDa 
202241_at  TRIB1  tribbles homolog 1 (Drosophila) 
228855_at  NUDT7  nudix (nucleoside diphosphate linked moiety X)-type motif 7 
209854_s_at  KLK2  kallikrein-related peptidase 2 
201670_s_at  MARCKS  myristoylated alanine-rich protein kinase C substrate 
225864_at  FAM84B  family with sequence similarity 84, member B 
210102_at  vwa5a  von Willebrand factor A domain containing 5A 
244741_s_at  MGC9913  hypothetical protein MGC9913 
242064_at  sdk2  sidekick homolog 2 (chicken) 
201540_at  fhl1  four and a half LIM domains 1 
227013_at  Lats2  LATS, large tumor suppressor, homolog 2 (Drosophila) 
220066_at  NOD2  nucleotide-binding oligomerization domain containing 2 
228297_at  cnn3  calponin 3, acidic 
211640_x_at  IGHV1-69  immunoglobulin heavy variable 1-69; similar to hCG1773549 
211640_x_at  LOC100133862  immunoglobulin heavy variable 1-69; similar to hCG1773549 
219302_s_at  CNTNAP2  contactin associated protein-like 2 
232821_at  GTSF1L  gametocyte specific factor 1-like 
204334_at  KLF7  Kruppel-like factor 7 (ubiquitous) 
235570_at  RBMS3  RNA binding motif, single stranded interacting protein 
203548_s_at  Lpl  lipoprotein lipase 
238870_at  KCNK9  potassium channel, subfamily K, member 9 
226485_at  VSIG10  hypothetical protein FLJ20674 
228494_at  ppp1r9a  protein phosphatase 1, regulatory (inhibitor) subunit 9A 
236894_at  L1TD1  LINE-1 type transposase domain containing 1 
227529_s_at  AKAP12  A kinase (PRKA) anchor protein 12 
1552736_a_at  NETO1  neuropilin (NRP) and tolloid (TLL)-like 1 
206983_at  CCR6  cyclin L2; chemokine (C-C motif) receptor 6 
206983_at  Ccnl2  cyclin L2; chemokine (C-C motif) receptor 6 
212190_at  SERPINE2  serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 
236600_at  spg20  spastic paraplegia 20 (Troyer syndrome) 
226517_at  BCAT1  branched chain aminotransferase 1, cytosolic 
202555_s_at  MYLK  myosin light chain kinase 
231358_at  mro  maestro 34 
235616_at  TSHZ2  teashirt zinc finger homeobox 2 
200897_s_at  palld  palladin, cytoskeletal associated protein 
223595_at  TMEM133  transmembrane protein 133 
203549_s_at  Lpl  lipoprotein lipase 
203705_s_at  FZD7  frizzled homolog 7 (Drosophila) 
232383_at  TFEC  transcription factor EC 
205771_s_at  AKAP7  A kinase (PRKA) anchor protein 7 
210612_s_at  SYNJ2  synaptojanin 2 
202599_s_at  NRIP1  nuclear receptor interacting protein 1 
203641_s_at  Cobll1  COBL-like 1 
219737_s_at  PCDH9  protocadherin 9 
235743_at  SNED1  sushi, nidogen and EGF-like domains 1 
243375_at  GRIK1  glutamate receptor, ionotropic, kainate 1 
210644_s_at  Lair1  leukocyte-associated immunoglobulin-like receptor 1 
204731_at  Tgfbr3  transforming growth factor, beta receptor III 
219496_at  ANKRD57  ankyrin repeat domain 57 
205992_s_at  IL15  interleukin 15 
209732_at  CLEC2B  C-type lectin domain family 2, member B 
204072_s_at  FRY  furry homolog (Drosophila) 
226625_at  Tgfbr3  transforming growth factor, beta receptor III 
215767_at  ZNF804A  zinc finger protein 804A 
213714_at  CACNB2  calcium channel, voltage-dependent, beta 2 subunit 
235800_at  ENO4  chromosome 10 open reading frame 134 
221261_x_at  MAGED4B  melanoma antigen family D, 4B; melanoma antigen family D, 4 
221261_x_at  MAGED4  melanoma antigen family D, 4B; melanoma antigen family D, 4 
218613_at  PSD3  pleckstrin and Sec7 domain containing 3 
213906_at  mybl1  v-myb myeloblastosis viral oncogene homolog (avian)-like 1 
206865_at  HRK  harakiri, BCL2 interacting protein (contains only BH3 domain) 
239246_at  FARP1  FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived) 
212655_at  ZCCHC14  zinc finger, CCHC domain containing 14 
227792_at  Itpripl2  inositol 1,4,5-triphosphate receptor interacting protein-like 2 
213093_at  Prkca  protein kinase C, alpha 
212503_s_at  dip2c  DIP2 disco-interacting protein 2 homolog C (Drosophila) 
236635_at  ZNF667  zinc finger protein 667 
227034_at  ANKRD57  ankyrin repeat domain 57 
227810_at  ZNF558  zinc finger protein 558 
229347_at  LOC729506  hypothetical LOC729506 
244521_at  TSHZ2  teashirt zinc finger homeobox 2 
214452_at  BCAT1  branched chain aminotransferase 1, cytosolic 
206115_at  EGR3  early growth response 3 
1562713_a_at  NETO1  neuropilin (NRP) and tolloid (TLL)-like 1 
230793_at  Lrrc16a  leucine rich repeat containing 16A 
223535_at  NUDT12  nudix (nucleoside diphosphate linked moiety X)-type motif 12 
214953_s_at  APP  amyloid beta (A4) precursor protein 
1556839_s_at  SPTBN5  spectrin, beta, non-erythrocytic 5 
201669_s_at  MARCKS  myristoylated alanine-rich protein kinase C substrate 35 
243940_at  TSHZ2  teashirt zinc finger homeobox 2 
212526_at  spg20  spastic paraplegia 20 (Troyer syndrome) 
233985_x_at  ppp1r9a  protein phosphatase 1, regulatory (inhibitor) subunit 9A 
224361_s_at  Il17rb  interleukin 17 receptor B 
201876_at  PON2  paraoxonase 2 
238447_at  RBMS3  RNA binding motif, single stranded interacting protein 
1569346_a_at  P2RX1  purinergic receptor P2X, ligand-gated ion channel, 1 
225285_at  BCAT1  branched chain aminotransferase 1, cytosolic 
224823_at  MYLK  myosin light chain kinase 
219841_at  AICDA  activation-induced cytidine deaminase 
211634_x_at  IGHV1-69  immunoglobulin heavy variable 1-69; similar to hCG1773549 
211634_x_at  LOC100133862  immunoglobulin heavy variable 1-69; similar to hCG1773549 
216620_s_at  arhgef10  Rho guanine nucleotide exchange factor (GEF) 10 
203029_s_at  Ptprn2  protein tyrosine phosphatase, receptor type, N polypeptide 2 
202342_s_at  trim2  tripartite motif-containing 2 
204647_at  HOMER3  homer homolog 3 (Drosophila) 
211635_x_at  IGHV1OR15-9 
V-set and immunoglobulin domain containing 7; 
immunoglobulin heavy variable 1/OR15-5 pseudogene; 
immunoglobulin heavy variable 1/OR15-9 (non-functional) 
211635_x_at  VSIG7 
V-set and immunoglobulin domain containing 7; 
immunoglobulin heavy variable 1/OR15-5 pseudogene; 
immunoglobulin heavy variable 1/OR15-9 (non-functional) 
211635_x_at  IGHV1OR21-1 
V-set and immunoglobulin domain containing 7; 
immunoglobulin heavy variable 1/OR15-5 pseudogene; 
immunoglobulin heavy variable 1/OR15-9 (non-functional) 
241278_at  FCRL3  Fc receptor-like 3 
226164_x_at  RIMKLB  ribosomal modification protein rimK-like family member B 
225330_at  IGF1R  insulin-like growth factor 1 receptor 
228532_at  C1orf162  chromosome 1 open reading frame 162 
207245_at  UGT2B17  UDP glucuronosyltransferase 2 family, polypeptide B17 
1560225_at  cnr1  cannabinoid receptor 1 (brain) 
205419_at  Gpr183  G protein-coupled receptor 183 
238577_s_at  TSHZ2  teashirt zinc finger homeobox 2 
228033_at  E2F7  E2F transcription factor 7 
217371_s_at  IL15  interleukin 15 
221337_s_at  ADAM29  ADAM metallopeptidase domain 29 
203355_s_at  PSD3  pleckstrin and Sec7 domain containing 3 
223696_at  arsD  arylsulfatase D 
203795_s_at  BCL7A  B-cell CLL/lymphoma 7A 
204439_at  IFI44L  interferon-induced protein 44-like 
203881_s_at  dmd  dystrophin 
213436_at  cnr1  cannabinoid receptor 1 (brain) 
225140_at  KLF3  Kruppel-like factor 3 (basic) 
226247_at  plekha1  pleckstrin homology domain containing, family A (phosphoinositide binding specific) 
member 1 
238512_at  CAPZA1  capping protein (actin filament) muscle Z-line, alpha 1 
202600_s_at  NRIP1  nuclear receptor interacting protein 1 
216541_x_at  IGHV1-69  immunoglobulin heavy variable 1-69; similar to hCG1773549 
216541_x_at  LOC100133862  immunoglobulin heavy variable 1-69; similar to hCG1773549 
226846_at  phyhd1  phytanoyl-CoA dioxygenase domain containing 1 36 
1569345_at  P2RX1  purinergic receptor P2X, ligand-gated ion channel, 1 
224499_s_at  AICDA  activation-induced cytidine deaminase 
238778_at  MPP7  membrane protein, palmitoylated 7 (MAGUK p55 subfamily member 7) 
221704_s_at  vps37b  vacuolar protein sorting 37 homolog B (S. cerevisiae) 
230673_at  PKHD1L1  polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 
200602_at  APP  amyloid beta (A4) precursor protein 
231093_at  FCRL3  Fc receptor-like 3 
232820_s_at  GTSF1L  gametocyte specific factor 1-like 
228737_at  TOX2  TOX high mobility group box family member 2 
219955_at  L1TD1  LINE-1 type transposase domain containing 1 
211633_x_at  IGHV3-11 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 
211633_x_at  IGHV3-7 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 
211633_x_at  IGHG3 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 
211633_x_at  Ighg1 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 
211633_x_at  IGH@ 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 
211633_x_at  IGHM 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 
211633_x_at  ighv4-31 
immunoglobulin heavy constant gamma 1 (G1m marker); 
immunoglobulin heavy constant mu; immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); 
immunoglobulin heavy variable 4-31; immunoglobulin heavy locus 
222457_s_at  LIMA1  LIM domain and actin binding 1 
214039_s_at  Laptm4b  lysosomal protein transmembrane 4 beta 
203695_s_at  Dfna5  deafness, autosomal dominant 5 
204255_s_at  VDR  vitamin D (1,25- dihydroxyvitamin D3) receptor 
201911_s_at  FARP1  FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived) 
206486_at  LAG3  lymphocyte-activation gene 3 
229598_at  Cobll1  COBL-like 1 
222258_s_at  SH3BP4  SH3-domain binding protein 4 
210517_s_at  AKAP12  A kinase (PRKA) anchor protein 12 
238919_at  PCDH9  protocadherin 9 
228974_at  ZNF677  zinc finger protein 677 
221088_s_at  ppp1r9a  protein phosphatase 1, regulatory (inhibitor) subunit 9A 37 
213056_at  FRMD4B  FERM domain containing 4B 
227379_at  MBOAT1  membrane bound O-acyltransferase domain containing 1 
203706_s_at  FZD7  frizzled homolog 7 (Drosophila) 
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Section 6 
APPLICATION TO 
WALDENSTRÖM’S 
MACROGLOBULINEMIA AND IgM 
MGUS 
The  second  application  that  with  considered  in  this  thesis  regarded  IgM  monoclonal 
gammopathy  of  undetermined  significance  and  Waldensström’s  macroglobulinemia.  In 
particular we were concerned by the possible evolution of the former one in the latter one. 
 
 
6.1.  Gene selection 
As explained in 2.2, this data set consisted in 97 probes extracted from different cell types. The 
first problem we had to deal with was a strong batch effect on microarray data. Batch effect, that 
is a non biological experimental variation, is pretty common in microarray experiments and it 
makes it inappropriate to combine data sets without adjusting for it. We used a function which 
exploits an empirical Bayesian framework (19). Named function is ComBat in the sva R package 
of Bioconductor (20). 
The next step consisted in performing a SAM selection (15) only on genes belonging to those 
microarrays extracted from antigen CD19 positive cells. By using a false discorvery rate of 5%, 
we obtained 750 genes for each of the 38 samples. These samples, corresponding to as many 
individuals, presented two different diagnosis: 
1.  IgM MGUS: 11 patients (referred to as “MGUS”); 
2.  WM: 27 patients (referred to as “WM”). 
This subset is referred to as WM_MGUS_38. 40 
 
WM_MGUS_38 
Class name  # of patients  Diagnosis 
MGUS  11  IgM MGUS 
WM 2  27  WM 
Table 7 
 
 
6.2.  SPD results 
We had to make some attempts before having good results according to the trend of the relative 
classification error and hence the ability to distinguish between the two pathological conditions. 
At first, we divided the data set in 3 subsets of probes. Each subset consisted of the same number 
of genes, i.e. 54675 as no gene selection was performed, and samples were grouped together 
according to the cell type: CD19
+, CD138
+, NEG. SPD wasn’t able to retrieve a progression 
representative of the different diagnosis for the two latter subsets, and results on the former 
subset  were  affected  by  the  large  number  of  genes,  as  expected.  We  then  performed  gene 
selection for each group, with the method explained in section 6.1. Again results for CD138
+ and 
NEG groups were not outstanding, meaning that the information content is in CD19
+ cells. 
 
 
Figure 10 
 
The relative classification error, shown in Figure 10, was computed by counting the number of 
sample  swaps  needed  to  have  the  right  classification,  and  dividing  by  the  total  number  of 
samples, namely 38. 
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Results  gained  on  subset  WM_MGUS_38  were  satisfactory,  as  the  trend  of  the  relative 
classification error showed: the average relative error is approximately 5.3%. SPD was capable 
of  distinguishing  between  IgM  MGUS and WM patients. For a restricted range of standard 
deviation threshold values the number of filtered genes was constant, as consequently was the 
correspondent error.  
 
 
Figure 11 
 
In Figure 11, we show one of the progressions made by SPD for standard deviation threshold set 
to 0.5. 
For this subset of genes, other labels for each probe were available: WM label, bone marrow 
infiltration percentage, sex and age, as reported in Table 10. For each progression given by SPD, 
we checked if patients were classified according to some labels other than diagnosis. None of the 
progressions reflected the partition of patients according to any other labels. 
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Table 8 - Correspondence between SPD samples and microarray 
#  /  Probe Name 
1  /  2001_02_22_WM03_CD19_U133_PLUS2 
2  /  2010_02_16_WM02_CD19 
3  /  2010_03_15_WM01_CD19_U133_PLUS2 
4  /  2010_03_25_WM04_CD19_U133_PLUS2 
5  /  2010_03_25_WM06_CD19_U133_PLUS2 
6  /  2010_03_31_WM07_CD19 
7  /  2010_03_31_WM08_CD19 
8  /  2010_04_08_WM09_CD19_PLUS2 
9  /  2010_05_07_WM13_19_U133_PLUS2 
10  /  2010_05_11_WM12_CD19_U133_PLUS2 
11  /  2010_08_27_WM18_CD19_U133_PLUS2 
12  /  2010_08_27_WM19_CD19_U133_PLUS2 
13  /  2010_08_31_WM15_CD19_U133_PLUS2 
14  /  2010_09_03_WM21_CD19_U133_PLUS2 
15  /  2011_02_18_WM22_CD19_U133_PLUS2 
16  /  2011_02_24_WM23_CD19_U133_PLUS2 
17  /  2011_03_01_MGUS02_CD19_U133_PLUS2 
18  /  2011_03_02_MGUS03_CD19_U133_PLUS2 
19  /  2011_05_17_WM24PV_CD19_U133_PLUS2 
20  /  2011_05_20_WM25PV_CD19_U133_PLUS2 
21  /  2011_05_20_WM31_CD19_U133_PLUS2 
22  /  2011_06_09_WM26_CD19_U133_PLUS2 
23  /  2011_06_09_WM27_CD19_U133_PLUS2 
24  /  2011_06_17_WM28_CD19_U133_PLUS2 
25  /  2011_09_20_WM35_CD19_U133_PLUS2 
26  /  2011_10_27_MGUS16_CD19_U133_PLUS2 
27  /  2012_01_11_WM05_CD19_U133PLUS2 
28  /  2012_01_18_MGUS22_CD19_U133PLUS2 
29  /  2012_04_11_MGUS24_CD19 
30  /  2012_04_11_MGUS25_CD19 
31  /  2012_04_11_MGUS28_CD19 
32  /  2012_06_21_WM37_CD19 
33  /  2012_06_29_MGUS17_CD19_2 
34  /  2012_06_29_MGUS21_CD19_2 
35  /  2012_07_04_WM39_CD19 
36  /  2012_07_04_WM41_CD19 
37  /  2012_07_04_WM42_CD19 
38  /  2012_07_04_WM43_CD19 43 
 
Table 9 
PROBE ID  GENE ID  GENE NAME 
232687_at  GPRIN3  GPRIN family member 3 
1562153_a_at  PVT1  Pvt1 oncogene (non-protein coding) 
224156_x_at  Il17rb  interleukin 17 receptor B 
1562754_at  LOC339260  hypothetical protein LOC339260 
230793_at  Lrrc16a  leucine rich repeat containing 16A 
215767_at  ZNF804A  zinc finger protein 804A 
1553333_at  C1orf161  chromosome 1 open reading frame 161 
218309_at  Camk2n1  calcium/calmodulin-dependent protein kinase II inhibitor 1 
203404_at  ARMCX2  armadillo repeat containing, X-linked 2 
210550_s_at  RASGRF1  Ras protein-specific guanine nucleotide-releasing factor 1 
1564077_at  GPRIN3  GPRIN family member 3 
1556697_at  GPRIN3  GPRIN family member 3 
203215_s_at  myo6  myosin VI 
212935_at  MCF2L  MCF.2 cell line derived transforming sequence-like 
224361_s_at  Il17rb  interleukin 17 receptor B 
226408_at  TEAD2  TEA domain family member 2 
209498_at  CEACAM1  carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 
228560_at  Cacna1d  calcium channel, voltage-dependent, L type, alpha 1D subunit 
225757_s_at  CLMN  calmin (calponin-like, transmembrane) 
229656_s_at  Eml6  echinoderm microtubule associated protein like 6 
229147_at  rassf6  Ras association (RalGDS/AF-6) domain family member 6 
227556_at  NME7  non-metastatic cells 7, protein expressed in (nucleoside-diphosphate kinase) 
210640_s_at  GPER  G protein-coupled estrogen receptor 1 
1560762_at  LOC285972  hypothetical protein LOC285972 
242785_at  Eml6  echinoderm microtubule associated protein like 6 
219255_x_at  Il17rb  interleukin 17 receptor B 
 
 
As for subset CLL_114, we evaluated the union and the intersection of the genes used to build 
each progression given by standard deviation threshold values ranging from 0 to 1.5. Union 
included 739 genes, not reported, whereas the intersection included 31 genes, as represented in 
Table 9. None of them was found in literature as being related to the evolution of IgM MGUS in 
WM. 
For the sake of completeness, we performed a functional annotation clustering on genes reported 
in Table 9, as in 5.2. Results are not reported as fdr values were too high, i.e. greater than 5%. 
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Section 7 
DISCUSSION 
Within the study of pathological conditions starting from the analysis of high-throughput data, 
the usual approach consists in using supervised classification algorithms. The initial information 
about classes, usually two, is given by clinicians and is often affected by uncertainty. As emerges 
from literature, the supervised approach frequently fails, for two main reasons: the definition of 
classes is a tough task itself, and each sample belongs to a different stage along the disease 
progression. 
 
The rationale was to  exploit an unsupervised approach to  arrange samples, according to the 
progression state of a disease. To do so, we used a tool, Sample Progression Discovery (SPD), 
developed by Peng Qiu et al. (1), that, starting from gene expression data, seeks to retrieve 
sample position along a biologically meaningful progression, and extracts genes responsible for 
such progression. 
We then applied SPD to two pathological conditions: chronic lymphocytic leukemia (CLL) and 
Waldenström’s macroglobulinemia (WM). To the purpose, we had to evaluate the reliability of 
SPD results, first. Indeed, they depend on the input provided (gene selection) and SPD internal 
parameter setting. 
 
We used a data set consisting of 89 patients, who were diagnosed CLL, with a well defined 
prognosis. We tried different methods of gene selection and, for each of the subsets we obtained, 
we varied parameter values. We then evaluated quality of the results relying on SPD ability to 
classify patients in the right prognostic class. This former analysis proved that gene selection is 
essential, the best method being Significance Analysis of Microarrays (15) with false discovery 
rate threshold 5%; it is also necessary to evaluate outputs with parameter values. 
 
That said, we were enabled to focus on the application of SPD to hematological neoplasms. 
We  considered  two  distinct  hematological  neoplasms:  chronic  lymphocytic  leukemia  and 
Waldenström’s macroglobulinemia. Both of them are B-cell malignancies, often compared in the 46 
literature, but we studied them separately, as finding differences or similarities between them 
was beyond our aims (21). 
One reason to choose CLL is because this is a widespread disease within the population. Indeed, 
it’s one of the most common types of leukemia and, though it has been widely studied, the 
definition of prognostic classes is not well established yet. We then explored the possibility of 
using SPD to help us finding prognostic factors and supporting doctor’s decisions. 
As to Waldenström’s macroglobulinemia, the reason that prompted us to focus on it was the 
following. The etiology of WM is largely unknown. Patients with IgM monoclonal gammopathy 
of undetermined significance (IgM MGUS) are at the greatest risk of developing WM compared 
to the general population, and, therefore, MGUS is considered a precursor of WM 
 
For CLL, guidelines based on prognosis biomarkers have already been established, but not all 
patients behave according to such guidelines. It was proven that un-mutated IgVH and ZAP70 
positive expression is related to a poor prognosis, whereas mutated IgVH and ZAP70 negative 
expression corresponds to a positive prognosis. We submitted to SPD a data set that included 
patients not respecting such classification, hence with undefined prognosis, and a single patient 
with  non  available  prognosis.  The  result  given  by  SPD  was  a  progression  in  which  poor 
prognosis  patients  were  isolated  from  the  others,  who  were  mixed  together.  A  possible 
explanation is that undefined prognosis patients should be treated the same way as those with a 
positive prognosis. We also evaluated genes used by SPD to get to the progression. Some of 
them have already been studied and found to be correlated to the disease progression (8). Further 
analysis is needed, since most of the genes involved in building the progression still have to be 
evaluated. 
 
Nowadays,  it  is  a  well  established notion  that  a subset of  IgM  monoclonal gammopathy  of 
undetermined significance represents the precursor state of Waldenström’s macroglobulinemia 
(21). We used a data set consisting of 38 patients, 11 of them diagnosed IgM MGUS and the 
other 27 suffering from WM. SPD was able to recover a progression characterized by patients 
being grouped together according to their diagnosis. Such result is only a starting point. First of 
all it confirms that the gene selection made was actually appropriate for SPD, since noise due to 
all  gene  expression  values  was  reduced.  On  the  other  hand,  genes  extracted  to  build  the 
progression have to be further studied, as it is not yet clear what is responsible for the evolution 
of IgM MGUS into WM. 
 47 
Even if Sample Progression Discovery results are strongly affected by the way input is prepared, 
it can be a powerful tool. Indeed, it was capable of recognizing patient membership to their own 
class,  according  to  gene  expression  profiles,  thus  providing  at  least  an  idea  on  the  disease 
evolution  and  on  how  to  handle  uncertain  situations.  Moreover,  it  detects  genes  underlying 
progressions. 
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Section 9 
APPENDIX  
Table 10 
CHIP ID  DIAGNOSIS  WM LABEL  BONE MARROW INFILTRATION [%]  SEX  AGE (at blood sample)  PATIENT ID 
2001_02_22_WM03_CD19_U133_PLUS2  WM  1  90  F  79.5  WM03 
2010_02_16_WM02_CD19  WM  1  90  F  53.9  WM02 
2010_03_15_WM01_CD19_U133_PLUS2  WM  1  50  F  80.9  WM01 
2010_03_25_WM04_CD19_U133_PLUS2  WM  2  30  F  77.2  WM04 
2010_03_25_WM06_CD19_U133_PLUS2  WM  3  10  F  73  WM06 
2010_03_31_WM07_CD19  WM  2  30  M  70.1  WM07 
2010_03_31_WM08_CD19  WM  2  50  F  76.7  WM08 
2010_04_08_WM09_CD19_PLUS2  WM  3  50  F  53.6  WM09 
2010_05_07_WM13_19_U133_PLUS2  WM  3  10  F  65.8  WM13 
2010_05_11_WM12_CD19_U133_PLUS2  IgM MGUS  5  2  M  65.6  MGUS19/WM12 
2010_08_27_WM18_CD19_U133_PLUS2  WM  2  30  M  78.4  WM18 
2010_08_27_WM19_CD19_U133_PLUS2  WM  2  70  F  65.7  WM19 
2010_08_31_WM15_CD19_U133_PLUS2  WM  3  80  F  75.6  WM15 
2010_09_03_WM21_CD19_U133_PLUS2  WM  3  20  F  73.7  WM21/MGUS11 
2011_02_18_WM22_CD19_U133_PLUS2  IgM MGUS  5  9  F  76.5  MGUS12/WM22 
2011_02_24_WM23_CD19_U133_PLUS2  WM  1  80  M  69.7  WM23 
2011_03_01_MGUS02_CD19_U133_PLUS2  WM  2  90  F  80.5  WM33/MGUS02 
2011_03_02_MGUS03_CD19_U133_PLUS2  WM  3  50  M  63.3  WM34/MGUS03 
2011_05_17_WM24PV_CD19_U133_PLUS2  IgM MGUS  5  0  F  76.1  MGUS18/WM24PV 
2011_05_20_WM25PV_CD19_U133_PLUS2  WM  3  45  M  64.3  WM25PV 
2011_05_20_WM31_CD19_U133_PLUS2  WM  3  40  M  78  WM31/MGUS07 
2011_06_09_WM26_CD19_U133_PLUS2  IgM MGUS  5  0  F  62.4  MGUS20/WM26 
2011_06_09_WM27_CD19_U133_PLUS2  WM  2  30  M  86.7  WM27 
2011_06_17_WM28_CD19_U133_PLUS2  WM  3  10  F  62.9  WM28 
2011_09_20_WM35_CD19_U133_PLUS2  WM  3  70  F  61.9  WM35/MGUS14  
2011_10_27_MGUS16_CD19_U133_PLUS2  IgM MGUS  5  0  M  72.3  MGUS16 
2012_01_11_WM05_CD19_U133PLUS2  WM  3  10  F  71.3  WM05 
2012_01_18_MGUS22_CD19_U133PLUS2  IgM MGUS  5  9  F  58.4  MGUS22/WM36 
2012_04_11_MGUS24_CD19  IgM MGUS  5  0  M  75.9  MGUS24 
2012_04_11_MGUS25_CD19  IgM MGUS  5  9  F  73.9  MGUS25 
2012_04_11_MGUS28_CD19  IgM MGUS  5  0  M  75.4  MGUS28 
2012_06_21_WM37_CD19  WM  3  30  M  77.8  WM37 
2012_06_29_MGUS17_CD19_2  IgM MGUS  5  0  M  70.6  MGUS17 
2012_06_29_MGUS21_CD19_2  IgM MGUS  5  9  F  80.5  MGUS21 
2012_07_04_WM39_CD19  WM  3  30  M  69.7  WM39 
2012_07_04_WM41_CD19  WM  2  50  M  55.4  WM41 
2012_07_04_WM42_CD19  WM  3  50  M  74.3  WM42 
2012_07_04_WM43_CD19  WM  3  10  F  70.5  WM43 
 
 
 
    
Table 11 
Annotation Cluster 1  Enrichment Score: 1.9161           
Category  Term  Count  %  PValue  Genes  FDR 
GOTERM_MF_FAT  GO:0005539~glycosaminoglycan 
binding  6  4.0541  0.0038  LPL, APP, NOD2, SERPINE2, TGFBR3, PTCH1  0.0488 
GOTERM_MF_FAT  GO:0001871~pattern binding  6  4.0541  0.0057  LPL, APP, NOD2, SERPINE2, TGFBR3, PTCH1  0.0721 
GOTERM_MF_FAT  GO:0030247~polysaccharide 
binding  6  4.0541  0.0057  LPL, APP, NOD2, SERPINE2, TGFBR3, PTCH1  0.0721 
GOTERM_MF_FAT  GO:0008201~heparin binding  5  3.3784  0.0071  LPL, APP, SERPINE2, TGFBR3, PTCH1  0.0897 
GOTERM_MF_FAT  GO:0030246~carbohydrate 
binding  7  4.7297  0.0472  LPL, APP, NOD2, SERPINE2, CLEC2B, TGFBR3, PTCH1  0.4717 
SP_PIR_KEYWORDS  heparin-binding  3  2.0270  0.0784  LPL, APP, SERPINE2  0.6499 
             
Annotation Cluster 2  Enrichment Score: 1.8333           
Category  Term  Count  %  PValue  Genes  FDR 
SP_PIR_KEYWORDS  actin-binding  10  6.7568  0.0001  PPP1R9A, LIMA1, SPTBN5, CNN3, DMD, CAPZA1, MARCKS, TPM2, PALLD, MYLK  0.0009 
GOTERM_MF_FAT  GO:0003779~actin binding  10  6.7568  0.0007  PPP1R9A, LIMA1, SPTBN5, CNN3, DMD, CAPZA1, MARCKS, TPM2, PALLD, MYLK  0.0089 
GOTERM_MF_FAT  GO:0008092~cytoskeletal 
protein binding  12  8.1081  0.0012  PPP1R9A, FRMD5, LIMA1, SPTBN5, CNN3, DMD, CAPZA1, MARCKS, TPM2, PALLD, 
FARP1, MYLK  0.0158 
SP_PIR_KEYWORDS  cytoskeleton  12  8.1081  0.0058  PPP1R9A, LIMA1, SPTBN5, DMD, FRMD4B, CAPZA1, AKAP12, MARCKS, TPM2, PALLD, 
SEPT10, LATS2  0.0726 
GOTERM_CC_FAT  GO:0005856~cytoskeleton  19  12.8378  0.0111  LIMA1, SPTBN5, CNN3, CAPZA1, PSD3, AKAP12, PALLD, TPM2, SEPT10, LATS2, FARP1, 
PPP1R9A, FRMD5, APP, HOMER3, DMD, FRMD4B, SYNJ2, MARCKS  0.1289 
GOTERM_CC_FAT  GO:0015629~actin cytoskeleton  7  4.7297  0.0143  PPP1R9A, LIMA1, SPTBN5, CAPZA1, MARCKS, TPM2, PALLD  0.1638 
GOTERM_CC_FAT  GO:0044430~cytoskeletal part  14  9.4595  0.0217  LIMA1, CNN3, SPTBN5, CAPZA1, PSD3, PALLD, TPM2, SEPT10, LATS2, APP, PPP1R9A, 
HOMER3, SYNJ2, MARCKS  0.2384 
GOTERM_BP_FAT  GO:0030036~actin cytoskeleton 
organization  5  3.3784  0.0793  PPP1R9A, LIMA1, SPTBN5, CNN3, CAPZA1  0.7356 
GOTERM_BP_FAT  GO:0007010~cytoskeleton 
organization  7  4.7297  0.0931  PPP1R9A, LIMA1, SPTBN5, CNN3, DMD, CAPZA1, PALLD  0.7924 
GOTERM_BP_FAT  GO:0030029~actin filament-
based process  5  3.3784  0.0950  PPP1R9A, LIMA1, SPTBN5, CNN3, CAPZA1  0.7993 
GOTERM_CC_FAT  GO:0043228~non-membrane-
bounded organelle  22  14.8649  0.3505  LIMA1, SPTBN5, CNN3, CAPZA1, PSD3, AKAP12, MYBL1, PALLD, TPM2, SEPT10, LATS2, 
FARP1, VDR, PPP1R9A, FRMD5, APP, HOMER3, DMD, FRMD4B, SYNJ2, MARCKS, MRO  0.9953 
GOTERM_CC_FAT  GO:0043232~intracellular non-
membrane-bounded organelle  22  14.8649  0.3505  LIMA1, SPTBN5, CNN3, CAPZA1, PSD3, AKAP12, MYBL1, PALLD, TPM2, SEPT10, LATS2, 
FARP1, VDR, PPP1R9A, FRMD5, APP, HOMER3, DMD, FRMD4B, SYNJ2, MARCKS, MRO  0.9953 
              
Annotation Cluster 4  Enrichment Score: 1.7209           
Category  Term  Count  %  PValue  Genes  FDR 
UP_SEQ_FEATURE  domain:Ig-like C2-type 3  6  4.0541  0.0019  VSIG10, SDK2, PALLD, MYLK, LAG3, FCRL3  0.0273 
UP_SEQ_FEATURE  domain:Ig-like C2-type 4  5  3.3784  0.0022  VSIG10, SDK2, PALLD, MYLK, FCRL3  0.0318 
INTERPRO  IPR013783:Immunoglobulin-like 
fold  12  8.1081  0.0026  VSIG10, IGHG1, LAIR1, IGHV1-69, IGHG3, SDK2, IGKV3D-15, LOC100133862, PALLD, 
IGHM, FCRL3, IGHV3-11, TRIM2, IGHV3-7, IGH@, IGHV4-31, LAG3, MYLK, LOC100126583  0.0349 
INTERPRO  IPR007110:Immunoglobulin-like  11  7.4324  0.0040  VSIG10, IGHG1, IGHV1-69, IGHG3, SDK2, IGKV3D-15, LOC100133862, PALLD, IGHM, 
SLAMF1, FCRL3, IGHV3-11, IGHV3-7, IGH@, IGHV4-31, LAG3, MYLK, LOC100126583  0.0527 
UP_SEQ_FEATURE  domain:Ig-like C2-type 5  4  2.7027  0.0072  SDK2, PALLD, MYLK, FCRL3  0.1016 
INTERPRO  IPR013106:Immunoglobulin V-
set  7  4.7297  0.0104  IGHG1, VSIG10, IGHV1-69, IGHG3, IGKV3D-15, LOC100133862, IGHM, FCRL3, IGHV3-11, 
IGHV3-7, IGH@, IGHV4-31, LAG3, LOC100126583  0.1322 
UP_SEQ_FEATURE  domain:Ig-like C2-type 1  6  4.0541  0.0120  VSIG10, SDK2, PALLD, MYLK, LAG3, FCRL3  0.1637 
UP_SEQ_FEATURE  domain:Ig-like C2-type 2  6  4.0541  0.0122  VSIG10, SDK2, PALLD, MYLK, LAG3, FCRL3  0.1669 
INTERPRO  IPR013151:Immunoglobulin  6  4.0541  0.0171  VSIG10, IGHV3-11, IGHG1, IGHG3, IGHV3-7, SDK2, IGHV4-31, IGH@, IGHM, LAG3, FCRL3, 
LOC100126583  0.2071 
SP_PIR_KEYWORDS  Immunoglobulin domain  9  6.0811  0.0194  IGHG1, VSIG10, LAIR1, IGHG3, SDK2, IGHM, PALLD, SLAMF1, FCRL3, IGHV3-11, IGHV3-
7, IGH@, IGHV4-31, LAG3, MYLK  0.2230 
INTERPRO  IPR003596:Immunoglobulin V-
set, subgroup  4  2.7027  0.0200  IGHV3-11, IGHG1, IGHV1-69, IGHG3, IGHV3-7, IGKV3D-15, LOC100133862, IGHV4-31, 
IGH@, IGHM, LOC100126583  0.2387 
UP_SEQ_FEATURE  domain:Ig-like C2-type 6  3  2.0270  0.0288  SDK2, MYLK, FCRL3  0.3520 
SMART  SM00406:IGv  4  2.7027  0.0333  IGHV3-11, IGHG1, IGHV1-69, IGHG3, IGHV3-7, IGKV3D-15, LOC100133862, IGHV4-31, 
IGH@, IGHM, LOC100126583  0.3064 
INTERPRO  IPR003598:Immunoglobulin 
subtype 2  5  3.3784  0.0655  VSIG10, SDK2, PALLD, MYLK, FCRL3  0.5991 
INTERPRO  IPR003599:Immunoglobulin 
subtype  6  4.0541  0.0977  VSIG10, LAIR1, SDK2, MYLK, LAG3, FCRL3  0.7504 
SMART  SM00408:IGc2  5  3.3784  0.1141  VSIG10, SDK2, PALLD, MYLK, FCRL3  0.7298 
SMART  SM00409:IG  6  4.0541  0.1775  VSIG10, LAIR1, SDK2, MYLK, LAG3, FCRL3  0.8789 
INTERPRO  IPR013098:Immunoglobulin I-
set  3  2.0270  0.2712  SDK2, PALLD, MYLK  0.9860 
             
Annotation Cluster 5  Enrichment Score: 1.6320           
Category  Term  Count  %  PValue  Genes  FDR 
GOTERM_CC_FAT  GO:0005886~plasma membrane  46  31.0811  0.0001 
IGHG1, IGHG3, LIMA1, GRIK1, IL15, IGHM, IL17RB, FCRL3, GNG8, APP, NOD2, FRMD5, 
HOMER3, SYNJ2, LAG3, PRKCA, LAIR1, PTPRN2, PSD3, PCDH9, MPP7, CCNL2, IGHV3-11, 
CCR6, CCR2, CYBRD1, AKAP7, IGH@, GPR183, CPM, AKAP12, CACNB2, NETO1, IGF1R, 
DMD, CLEC2B, CNR1, ZAP70, LPL, ADAM29, KL, SLAMF1, FZD7, IGHV3-7, PPP1R9A, 
GPR34, P2RX1, PON2, TGFBR3, IGHV4-31, PTCH1, FAM84B, PLEKHA1  0.0016  
GOTERM_CC_FAT  GO:0044459~plasma membrane 
part  31  20.9459  0.0004 
GPR183, LIMA1, GRIK1, CACNB2, IL15, IL17RB, GNG8, IGF1R, APP, HOMER3, DMD, 
CLEC2B, CNR1, ZAP70, SYNJ2, LAG3, ADAM29, KL, PTPRN2, PSD3, MPP7, SLAMF1, 
CCNL2, PPP1R9A, CCR6, GPR34, P2RX1, CCR2, CYBRD1, TGFBR3, AKAP7, PTCH1  0.0044 
GOTERM_CC_FAT  GO:0005887~integral to plasma 
membrane  18  12.1622  0.0055  GPR183, ADAM29, GRIK1, KL, PTPRN2, CACNB2, IL15, CCNL2, IL17RB, IGF1R, APP, CCR6, 
GPR34, P2RX1, CNR1, CLEC2B, CCR2, TGFBR3, PTCH1  0.0667 
GOTERM_CC_FAT  GO:0031226~intrinsic to plasma 
membrane  18  12.1622  0.0069  GPR183, ADAM29, GRIK1, KL, PTPRN2, CACNB2, IL15, CCNL2, IL17RB, IGF1R, APP, CCR6, 
GPR34, P2RX1, CNR1, CLEC2B, CCR2, TGFBR3, PTCH1  0.0826 
SP_PIR_KEYWORDS  receptor  21  14.1892  0.0085 
IGHG1, GPR183, IGHG3, GRIK1, IGHM, NETO1, FCRL3, IL17RB, VDR, IGF1R, CNR1, CRY1, 
LAIR1, PTPRN2, PKHD1L1, SLAMF1, FZD7, CCNL2, IGHV3-11, IGHV3-7, CCR6, GPR34, 
P2RX1, CCR2, TGFBR3, IGHV4-31, IGH@, PTCH1  0.1042 
SP_PIR_KEYWORDS  glycoprotein  44  29.7297  0.0097 
IGHG1, ARSD, IGHG3, GRIK1, IL15, IGHM, LASS6, IL17RB, FCRL3, APP, KCNK9, 
SERPINE2, DMKN, CNTNAP2, PDGFD, LAG3, VSIG10, LAIR1, PTPRN2, SDK2, PCDH9, 
PKHD1L1, CCNL2, IGHV3-11, UGT2B17, CCR6, CCR2, CYBRD1, IGH@, CPM, NETO1, 
IGF1R, CLEC2B, CNR1, FGL2, LPL, ADAM29, KLK2, KL, RNASE6, SLAMF1, LCN10, FZD7, 
IGHV3-7, GPR34, SNED1, P2RX1, PON2, TGFBR3, IGHV4-31, PTCH1  0.1174 
SP_PIR_KEYWORDS  signal  35  23.6486  0.0115 
IGHG1, CPM, IGHG3, ARSD, GRIK1, IL15, IGHM, FCRL3, NETO1, IL17RB, IGF1R, APP, 
SERPINE2, DMKN, CNTNAP2, FGL2, PDGFD, LAG3, VSIG10, LAIR1, LPL, ADAM29, KLK2, 
KL, PTPRN2, SDK2, RNASE6, PCDH9, PKHD1L1, LCN10, SLAMF1, FZD7, IGHV3-11, IGHV3-
7, UGT2B17, SNED1, ITPRIPL2, TGFBR3, PON2, IGHV4-31, IGH@  0.1378 
SP_PIR_KEYWORDS  cell membrane  26  17.5676  0.0117 
IGHG1, GPR183, IGHG3, CPM, GRIK1, CACNB2, IGHM, FCRL3, IL17RB, NETO1, GNG8, 
HOMER3, DMD, CNR1, ZAP70, PRKCA, LPL, LAIR1, KL, PSD3, PCDH9, SLAMF1, CCNL2, 
IGHV3-11, IGHV3-7, CCR6, GPR34, CCR2, TGFBR3, AKAP7, IGHV4-31, IGH@, PLEKHA1  0.1409 
UP_SEQ_FEATURE  signal peptide  35  23.6486  0.0126 
IGHG1, CPM, IGHG3, ARSD, GRIK1, IL15, IGHM, FCRL3, NETO1, IL17RB, IGF1R, APP, 
SERPINE2, DMKN, CNTNAP2, FGL2, PDGFD, LAG3, VSIG10, LAIR1, LPL, ADAM29, KLK2, 
KL, PTPRN2, SDK2, RNASE6, PCDH9, PKHD1L1, LCN10, SLAMF1, FZD7, IGHV3-11, IGHV3-
7, UGT2B17, SNED1, ITPRIPL2, TGFBR3, PON2, IGHV4-31, IGH@  0.1710 
UP_SEQ_FEATURE  glycosylation site:N-linked 
(GlcNAc...)  42  28.3784  0.0138 
IGHG1, ARSD, IGHG3, GRIK1, IL15, IGHM, LASS6, IL17RB, FCRL3, APP, KCNK9, 
SERPINE2, CNTNAP2, PDGFD, LAG3, VSIG10, LAIR1, PTPRN2, SDK2, PCDH9, CCNL2, 
IGHV3-11, UGT2B17, CCR6, CCR2, CYBRD1, IGH@, CPM, NETO1, IGF1R, CLEC2B, CNR1, 
FGL2, LPL, ADAM29, KLK2, KL, RNASE6, SLAMF1, LCN10, FZD7, IGHV3-7, GPR34, SNED1, 
P2RX1, PON2, TGFBR3, IGHV4-31, PTCH1  0.1856 
UP_SEQ_FEATURE  disulfide bond  30  20.2703  0.0265 
IGHG1, GPR183, IGHG3, CPM, IL15, IGHM, FCRL3, NETO1, IGF1R, APP, CLEC2B, 
CNTNAP2, FGL2, PDGFD, LAG3, VSIG10, LAIR1, LPL, ADAM29, KLK2, SDK2, RNASE6, 
PALLD, LCN10, SLAMF1, FZD7, CCNL2, IGHV3-11, IGHV3-7, CCR6, GPR34, P2RX1, SNED1, 
CCR2, PON2, IGHV4-31, IGH@  0.3280 
UP_SEQ_FEATURE  topological domain:Extracellular  29  19.5946  0.0288 
GPR183, GRIK1, IL17RB, NETO1, FCRL3, IGF1R, APP, KCNK9, CLEC2B, CNR1, CNTNAP2, 
LAG3, VSIG10, LAIR1, ADAM29, KL, PTPRN2, SDK2, PCDH9, PKHD1L1, SLAMF1, FZD7, 
CCNL2, CCR6, GPR34, P2RX1, ITPRIPL2, CCR2, TGFBR3, PTCH1  0.3520 
SP_PIR_KEYWORDS  membrane  56  37.8378  0.0360 
IGHG1, IGHG3, GRIK1, VPS37B, IGHM, LASS6, IL17RB, FCRL3, GNG8, APP, FRMD5, 
KCNK9, HOMER3, SYNJ2, CNTNAP2, LAG3, VSIG10, PRKCA, LAIR1, PTPRN2, SDK2, PSD3, 
PCDH9, MPP7, PKHD1L1, CCNL2, FRY, IGHV3-11, TMEM133, UGT2B17, CCR6, CCR2, 
CYBRD1, AKAP7, IGH@, GPR183, CPM, CACNB2, NETO1, IGF1R, CNR1, CLEC2B, DMD, 
ZAP70, LAPTM4B, LPL, C1ORF162, ADAM29, KL, SLAMF1, FZD7, SH3BP4, IGHV3-7, 
GPR34, P2RX1, ITPRIPL2, MBOAT1, TGFBR3, PON2, PTCH1, MARCKS, IGHV4-31, 
PLEKHA1  0.3761 
SP_PIR_KEYWORDS  disulfide bond  30  20.2703  0.0376  IGHG1, GPR183, IGHG3, CPM, IL15, IGHM, FCRL3, NETO1, IGF1R, APP, CLEC2B,  0.3895  
CNTNAP2, FGL2, PDGFD, LAG3, VSIG10, LAIR1, LPL, ADAM29, KLK2, SDK2, RNASE6, 
PALLD, LCN10, SLAMF1, FZD7, CCNL2, IGHV3-11, IGHV3-7, CCR6, GPR34, P2RX1, SNED1, 
CCR2, PON2, IGHV4-31, IGH@ 
GOTERM_BP_FAT 
GO:0007166~cell surface 
receptor linked signal 
transduction 
20  13.5135  0.0669  GPR183, ADAM29, GRIK1, KL, KLF10, AKAP12, FZD7, CCNL2, GNG8, IGF1R, APP, CCR6, 
GPR34, HOMER3, CNR1, CCR2, ZAP70, TGFBR3, PTCH1, LAG3, PLEKHA1  0.6722 
SP_PIR_KEYWORDS  transmembrane protein  9  6.0811  0.0884  IGF1R, GPR183, APP, CCR6, CNR1, PTPRN2, CCR2, TGFBR3, LAG3, CCNL2  0.6960 
UP_SEQ_FEATURE  topological domain:Cytoplasmic  30  20.2703  0.1654 
GPR183, GRIK1, LASS6, IL17RB, NETO1, FCRL3, IGF1R, APP, KCNK9, CLEC2B, CNR1, 
CNTNAP2, LAG3, VSIG10, LAIR1, ADAM29, KL, PTPRN2, SDK2, PCDH9, PKHD1L1, 
SLAMF1, FZD7, CCNL2, CCR6, GPR34, P2RX1, ITPRIPL2, CCR2, TGFBR3, PTCH1  0.9314 
GOTERM_CC_FAT  GO:0031224~intrinsic to 
membrane  45  30.4054  0.2534 
IGHG1, IGHG3, GRIK1, IL15, IGHM, LASS6, IL17RB, FCRL3, APP, FRMD5, KCNK9, 
CNTNAP2, LAG3, VSIG10, LAIR1, PTPRN2, SDK2, PCDH9, PKHD1L1, CCNL2, FRY, 
TMEM133, IGHV3-11, UGT2B17, CCR6, CCR2, CYBRD1, AKAP7, IGH@, GPR183, CPM, 
CACNB2, NETO1, IGF1R, CLEC2B, CNR1, LAPTM4B, LPL, C1ORF162, ADAM29, KL, 
SLAMF1, FZD7, IGHV3-7, GPR34, P2RX1, ITPRIPL2, MBOAT1, TGFBR3, IGHV4-31, 
MARCKS, PTCH1  0.9733 
SP_PIR_KEYWORDS  transmembrane  39  26.3514  0.3372 
IGHG1, GPR183, IGHG3, GRIK1, IGHM, LASS6, FCRL3, NETO1, IL17RB, IGF1R, FRMD5, 
APP, KCNK9, CNR1, CLEC2B, CNTNAP2, LAG3, VSIG10, LAPTM4B, LAIR1, C1ORF162, 
ADAM29, KL, PTPRN2, SDK2, PCDH9, PKHD1L1, SLAMF1, FZD7, CCNL2, FRY, IGHV3-11, 
TMEM133, IGHV3-7, UGT2B17, CCR6, GPR34, P2RX1, CCR2, ITPRIPL2, CYBRD1, MBOAT1, 
TGFBR3, PTCH1, IGHV4-31, IGH@  0.9950 
UP_SEQ_FEATURE  transmembrane region  38  25.6757  0.3938 
GPR183, GRIK1, LASS6, FCRL3, IL17RB, NETO1, IGF1R, FRMD5, APP, KCNK9, CLEC2B, 
CNR1, CNTNAP2, LAG3, VSIG10, LAPTM4B, LAIR1, C1ORF162, ADAM29, KL, PTPRN2, 
SDK2, PCDH9, PKHD1L1, SLAMF1, FZD7, CCNL2, FRY, TMEM133, UGT2B17, CCR6, GPR34, 
P2RX1, CCR2, ITPRIPL2, MBOAT1, CYBRD1, TGFBR3, PTCH1  0.9994 
GOTERM_CC_FAT  GO:0016021~integral to 
membrane  41  27.7027  0.4521 
IGHG1, GPR183, IGHG3, GRIK1, CACNB2, IL15, IGHM, LASS6, FCRL3, NETO1, IL17RB, 
IGF1R, FRMD5, APP, KCNK9, CNR1, CLEC2B, CNTNAP2, LAG3, VSIG10, LAPTM4B, LAIR1, 
C1ORF162, ADAM29, KL, PTPRN2, SDK2, PCDH9, PKHD1L1, SLAMF1, FZD7, CCNL2, FRY, 
IGHV3-11, TMEM133, IGHV3-7, UGT2B17, CCR6, GPR34, P2RX1, CCR2, ITPRIPL2, CYBRD1, 
MBOAT1, TGFBR3, PTCH1, IGHV4-31, IGH@  0.9994 
             
Annotation Cluster 7  Enrichment Score: 1.3862           
Category  Term  Count  %  PValue  Genes  FDR 
GOTERM_CC_FAT  GO:0043005~neuron projection  9  6.0811  0.0037  IGF1R, APP, PPP1R9A, KIAA1598, GPR34, CNN3, GRIK1, SYNJ2, APBB2  0.0444 
GOTERM_CC_FAT  GO:0042995~cell projection  10  6.7568  0.0702  IGF1R, APP, PPP1R9A, KIAA1598, GPR34, CNN3, GRIK1, CYBRD1, SYNJ2, APBB2  0.5948 
GOTERM_CC_FAT  GO:0044463~cell projection part  5  3.3784  0.0938  APP, PPP1R9A, CNN3, CYBRD1, SYNJ2  0.7054 
GOTERM_CC_FAT  GO:0030425~dendrite  4  2.7027  0.1185  PPP1R9A, GPR34, CNN3, GRIK1  0.7908 
 
 